Analysts at Stifel Reiterate their Past ‘Buy’ rating on Shares Loxo Oncology (NASDAQ:LOXO), Set a $217 Target Price per Share

August 10, 2018 - By Robert Crowder

Loxo Oncology, Inc. (NASDAQ:LOXO) Logo

Investors sentiment increased to 1.16 in 2018 Q1. Its up 0.19, from 0.97 in 2017Q4. It is positive, as 9 investors sold Loxo Oncology, Inc. shares while 53 reduced holdings. 32 funds opened positions while 40 raised stakes. 30.09 million shares or 75.89% less from 124.82 million shares in 2017Q4 were reported.

Mackay Shields Ltd Llc holds 8,600 shares or 0.01% of its portfolio. Franklin Resources holds 0.01% or 246,520 shares. Teacher Retirement Sys Of Texas has invested 0% in Loxo Oncology, Inc. (NASDAQ:LOXO). Voya Inv Ltd Liability Company holds 0.05% or 185,761 shares in its portfolio. Frontier Com Ltd Liability Corporation reported 86,302 shares or 0.07% of all its holdings. Vanguard Gru Incorporated invested in 2.11M shares. Sands Cap Mgmt Ltd Liability accumulated 2.13 million shares or 0.73% of the stock. State Of Wisconsin Inv Board has 0.01% invested in Loxo Oncology, Inc. (NASDAQ:LOXO) for 22,400 shares. Wells Fargo And Company Mn invested in 16,138 shares or 0% of the stock. Schwab Charles Inv Mngmt owns 0.01% invested in Loxo Oncology, Inc. (NASDAQ:LOXO) for 110,975 shares. Pinnacle Assocs invested in 0.03% or 12,025 shares. 285,511 are held by Northern Tru Corporation. Principal Grp Incorporated owns 8,515 shares. First Personal Services stated it has 0% of its portfolio in Loxo Oncology, Inc. (NASDAQ:LOXO). Zurcher Kantonalbank (Zurich Cantonalbank), Switzerland-based fund reported 1,083 shares.

Since February 12, 2018, it had 0 insider purchases, and 24 insider sales for $294.29 million activity. On Friday, June 8 MAYLEBEN TIMOTHY M sold $1.80M worth of Loxo Oncology, Inc. (NASDAQ:LOXO) or 10,000 shares. 1.40M Loxo Oncology, Inc. (NASDAQ:LOXO) shares with value of $251.20 million were sold by AISLING CAPITAL III LP. On Thursday, June 14 the insider Kunkel Lori Anne sold $7.06M. Burstein Jennifer had sold 1,700 shares worth $300,888. Another trade for 3,082 shares valued at $404,461 was made by Van Naarden Jacob on Tuesday, April 24. On Thursday, June 7 Flaherty Keith T. sold $8.68 million worth of Loxo Oncology, Inc. (NASDAQ:LOXO) or 50,000 shares.

Loxo Oncology (NASDAQ:LOXO) Rating Reaffirmed

Stifel now has a $217 price target on the $4.79 billion market cap company or 36.22 % upside potential. In an analyst note revealed to investors on Friday morning, Loxo Oncology (NASDAQ:LOXO) shares have had their Buy Rating maintained by research professionals at Stifel.

Loxo Oncology, Inc. (NASDAQ:LOXO) Ratings Coverage

Among 9 analysts covering Loxo Oncology (NASDAQ:LOXO), 8 have Buy rating, 0 Sell and 1 Hold. Therefore 89% are positive. Loxo Oncology has $225 highest and $132.0 lowest target. $192’s average target is 20.53% above currents $159.3 stock price. Loxo Oncology had 14 analyst reports since February 22, 2018 according to SRatingsIntel. On Wednesday, March 21 the stock rating was downgraded by Morgan Stanley to “Equal-Weight”. JMP Securities maintained Loxo Oncology, Inc. (NASDAQ:LOXO) on Monday, June 4 with “Market Outperform” rating. The firm has “Buy” rating by Stifel Nicolaus given on Thursday, March 1. Oppenheimer initiated Loxo Oncology, Inc. (NASDAQ:LOXO) rating on Thursday, February 22. Oppenheimer has “Buy” rating and $132.0 target. Morgan Stanley maintained it with “Overweight” rating and $215 target in Monday, June 4 report. The stock has “Buy” rating by Piper Jaffray on Wednesday, May 30. The stock of Loxo Oncology, Inc. (NASDAQ:LOXO) has “Buy” rating given on Wednesday, May 9 by Stifel Nicolaus. The firm earned “Buy” rating on Monday, March 5 by Citigroup. The stock of Loxo Oncology, Inc. (NASDAQ:LOXO) has “Market Perform” rating given on Tuesday, June 5 by IFS Securities. The stock of Loxo Oncology, Inc. (NASDAQ:LOXO) earned “Buy” rating by Stifel Nicolaus on Monday, June 4.

The stock decreased 0.04% or $0.07 during the last trading session, reaching $159.3. About 330,715 shares traded. Loxo Oncology, Inc. (NASDAQ:LOXO) has risen 248.86% since August 10, 2017 and is uptrending. It has outperformed by 236.29% the S&P500.

Loxo Oncology, Inc., a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. The company has market cap of $4.79 billion. The Company’s lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase , which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer. It currently has negative earnings. The companyÂ’s preclinical programs include LOXO-195, a drug candidate in preclinical development to address predicted acquired resistance mechanisms; RET inhibitor that optimizes potency for rearranged during transfection (RET) fusion proteins, mutations, and anticipated mechanisms of acquired resistance; and FGFR inhibitor that enables potently inhibiting FGFR isoforms comprising four isoforms with tyrosine kinase domains.

More notable recent Loxo Oncology, Inc. (NASDAQ:LOXO) news were published by: which released: “The Daily Biotech Pulse: Ampio Slides On Offering, Sangamo’s Positive Trial Results, Insys Earnings” on August 09, 2018, also with their article: “Loxo Oncology (LOXO) Announces Accepted Abstracts at IASLC” published on August 10, 2018, published: “Loxo Oncology Reports Second Quarter 2018 Financial Results” on August 09, 2018. More interesting news about Loxo Oncology, Inc. (NASDAQ:LOXO) were released by: and their article: “Loxo Oncology to Announce Second Quarter 2018 Financial Results” published on August 02, 2018 as well as‘s news article titled: “What Blueprint Medicines Just Said About Its Future” with publication date: August 02, 2018.

Loxo Oncology, Inc. (NASDAQ:LOXO) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: